Shanghai, China, 20th Nov 2026 —As artificial intelligence continues to reshape how people learn, communicate, and create, introducing children to technology is becoming about more than teaching them how to use digital tools. It is also about encouraging curiosity, creative thinking, and the confidence to explore new ideas.

As the creator of Pubbo AI, WhalesBot is bringing this approach into children’s everyday experiences through its AI creativity companion robot, designed for children ages 3 to 11. Combining conversational AI, visual recognition, creative expression, and hands-on coding activities, Pubbo AI offers children different ways to interact with technology, explore their surroundings, and turn their ideas into something tangible.

Bringing AI Interaction into Everyday Play

Rather than functioning as a traditional voice assistant or a toy built around repetitive activities, Pubbo AI encourages children to take an active role in each interaction.

Children can ask questions, discuss everyday topics, explore objects around them, and interact with the robot through voice and touch. Its AI-powered conversations and computer vision capabilities create opportunities for children to learn through observation and discovery, while its responsive expressions, sounds, and movements make interactions more engaging.

Pubbo AI also brings imagination into the experience through its Voice-to-Image feature. Children can describe an idea aloud and watch it become a digital image, creating a connection between spoken expression and visual creativity.

These experiences are designed to make AI more approachable for young learners, allowing them to encounter artificial intelligence through activities that feel familiar, interactive, and enjoyable.

Four Dimensions of Creativity at the Heart of Pubbo AI

Pubbo AI’s learning philosophy is built around four dimensions of creativity: Imagination, Expression, Exploration, and Design. Together, these dimensions shape how children interact with the robot and engage with new ideas.

Imagination begins with the freedom to think beyond familiar answers. Through AI conversations, storytelling, and Voice-to-Image creation, children can explore their ideas and turn their imagination into new possibilities.

Expression gives children opportunities to communicate what they think and feel. By asking questions, describing their ideas, and creating images through voice, children can practice expressing themselves in different ways.

Exploration encourages children to observe the world around them and discover how things work. Pubbo AI’s visual recognition capabilities allow children to explore objects, colors, and drawings, while interactive conversations and Challenge Mode introduce opportunities to ask questions, complete tasks, and learn through discovery.

Design brings ideas into action through hands-on creation. With Invention & Creation Mode, children can explore sensor-based interactions and experiment with robot behaviors. Free Coding Mode introduces visual coding blocks, allowing them to design the robot’s movements, lights, and sounds through their own programming ideas.

Rather than following only fixed instructions, children are encouraged to experiment, make adjustments, and discover different ways to bring their ideas to life.

Connecting AI Exploration with Hands-On Coding

Alongside its AI interaction features, Pubbo AI connects creative play with introductory coding experiences through the Pubbo App.

Challenge Mode introduces task-based activities that encourage children to explore and respond to different challenges. Invention & Creation Mode gives them opportunities to experiment with sensors and create interactive behaviors, while Free Coding Mode provides a more open-ended environment for designing robot actions through visual programming blocks.

These experiences introduce children to foundational ideas such as sequencing, cause and effect, and problem-solving. By seeing how their instructions influence the robot’s physical responses, children can connect abstract coding concepts with observable results.

This approach reflects WhalesBot’s broader interest in making technology and STEM learning more accessible through practical, engaging experiences.

 

Encouraging the Next Generation of Creative Thinkers

For WhalesBot, introducing children to AI and coding is not simply about preparing them to use the technologies of today. It is also about giving them opportunities to imagine, communicate, investigate, and create.

Through Pubbo AI, the company brings these ideas together in an interactive companion designed to make technology exploration part of everyday play. By combining AI-powered interaction with creative activities and hands-on coding, Pubbo AI encourages children to move beyond passive consumption and become active participants in their own learning experiences.

To learn more about Pubbo AI and its interactive features, visit the official website at https://pubbo.ai/.

About WhalesBot

Founded in 2018, WhalesBot is a globally recognized pioneer in robotics, programming tools, and AI learning systems. Driven by the mission to empower the next generation through hands-on technology, WhalesBot bridges hardware innovation, software development, and STEM curriculum into cohesive educational solutions.

WhalesBot operates across 81+ countries, partnering with over 30,000 schools and 20,000 educational institutions worldwide. Expanding from its leadership in educational robotics and international STEM competitions, WhalesBot created Pubbo AI to bring its deep hardware and pedagogical expertise directly into the home, delivering warm, creative, and inspiring AI companionship for families everywhere.

Media Contact

Organization: Shanghai WhalesBot Robotics Co., Ltd.

Contact Person: Shenleyan (Shen Leyan)

Website: https://www.whalesbot.com/

Email:
shenleyan@whalesbot.com

Contact Number: +8615021234738

Address: No. 188 Zixu Road, Minhang District, Shanghai, China

City: Shanghai

State: shanghai

Country: China

Release id: 50981

View source version on King Newswire:
WhalesBot Advances Creativity-Driven AI and Coding Education Through Pubbo AI

file

The St. Louis beverage company produces two fruit-and-botanical beverages using an approach that does not involve dealcoholizing wine.

Saint Louis, MO, United States, 20th Nov 2026 – Karviva, a St. Louis beverage company, produces Unwined, an alcohol-free beverage range available in Malbec-inspired and Rose-inspired varieties. The products are made from fruit and botanicals rather than from wine that has been fermented and then dealcoholized.

The Malbec-inspired variety combines organic aronia, dark cherry, mulberry, prickly pear and schisandra berry. The Rose-inspired variety is made with organic white grape, cranberry, rosehip, ginger, schisandra, saffron and organic artichoke inulin. Both varieties are USDA Organic, contain no added sugar and are shelf-stable. The Malbec-inspired formula contains no grape juice. Karviva recommends chilling the beverages before serving.

The products are part of a beverage category that is drawing attention as drinking habits change. Gallup’s 2026 Consumption Habits survey found that 54 percent of U.S. adults say they drink alcohol, matching the record low reported in 2025. The survey was conducted July 1-19, 2026. Gallup survey

Karviva produces its beverages at a facility in St. Louis. Founder Dr. Angela Zeng, Ph.D., MBA, a food scientist and Traditional Chinese Medicine scholar with training in pathology and biochemistry, established the facility after co-packers declined to produce her formulations.

“We developed Unwined as an alcohol-free beverage made from fruit and botanicals, with two distinct varieties,” said Dr. Zeng. “The Malbec-inspired and Rose-inspired formulas reflect our decision to work from the ingredients themselves rather than from dealcoholized wine.”

In 2025, Unwined received the Best Low/No Alcohol Beverage award at the World Beverage Innovation Awards, presented by FoodBev Media at drinktec in Munich. The awards announcement

About Karviva

Karviva is a beverage company founded by Dr. Angela Zeng, Ph.D., MBA, and based in St. Louis, Missouri. The company develops beverages using whole-plant ingredients, fruit, botanicals and hydroponically grown sprouts. Its product range includes Unwined, with Malbec-inspired and Rose-inspired varieties, as well as juice and Energy Juice products. Karviva products are made in St. Louis and are available in more than 2,000 retail locations nationwide. The company’s beverages are made without added sugar or artificial sweeteners and are non-GMO.

Karviva’s Energy Juice line received the 2025 ECRM Buyer’s Choice Award, and the line was included in Progressive Grocer’s 2026 Editors’ Picks. These recognitions relate to the Energy Juice products, not Unwined. ECRM award information | Progressive Grocer’s 2026 Editors’ Picks

Media Contact

Organization: Karviva

Contact Person: Dr. Angela Zeng

Website: https://karviva.com/

Email:
angela@karviva.com

City: Saint Louis

State: MO

Country: United States

Release id: 50805

View source version on King Newswire:
Karviva Introduces Unwined Alcohol-Free Malbec and Rose Varieties

file

The digital asset platform focuses on connecting spot trading, derivatives, commodity-related instruments, and tokenized asset services within a coordinated trading framework.

United States, 20th Nov 2026 – BIHE is continuing to develop its multi-asset trading service framework with a focus on connecting diversified trading instruments, account functionality, and product information within a coordinated digital environment. As demand for digital asset trading tools becomes more diverse, the company is emphasizing an integrated approach that goes beyond offering individual products. Its development strategy focuses on how different asset categories can be organized within a common service framework while maintaining the trading mechanisms, participation requirements, and operating conditions specific to each instrument.

According to the company, BIHE’s product development framework includes spot digital asset trading, USDT-margined perpetual contracts, standardized options, short-duration contracts, commodity contracts, and tokenized securities-related services. These categories represent different approaches to market participation and involve varying transaction structures, capital requirements, holding arrangements, and settlement mechanisms. 

By bringing these instruments into its broader development strategy, BIHE aims to create a more organized trading environment in which users can review product characteristics and understand relevant conditions through clearly structured information.

The integration of spot trading and derivatives forms an important component of BIHE’s multi-asset development approach. Spot transactions generally involve the purchase or sale of underlying digital assets, while perpetual contracts introduce additional considerations such as margin requirements, leverage, funding rates, and position management. Standardized options operate under specific contractual terms involving exercise conditions, expiration arrangements, and settlement procedures. Short-duration contracts may also involve distinct timing mechanisms and participation conditions. 

BIHE’s product framework recognizes these differences by emphasizing product-specific rules and information rather than treating all trading instruments as interchangeable services.

Beyond conventional digital asset trading tools, BIHE is also exploring development areas involving commodity contracts and tokenized securities-related services. Interest in these instruments reflects broader industry discussions about the relationship between digital trading infrastructure and different asset categories. Commodity-linked contracts may involve pricing mechanisms and settlement arrangements that differ from cryptocurrency transactions, while tokenized securities require consideration of underlying asset rights, investor eligibility, and applicable regulatory restrictions. 

BIHE identifies these distinctions as important factors when organizing its multi-asset product framework. The inclusion of such instruments within its development strategy does not necessarily indicate that every service is currently available in all jurisdictions.

Account functionality is another central element of the company’s integrated service approach. BIHE’s framework brings together market information displays, product selection, order placement, transaction records, and asset management functions. Users interacting with multiple trading instruments may need to review different account balances, position information, order histories, and transaction conditions. 

By coordinating these functions within a more consistent service structure, BIHE aims to reduce the complexity associated with navigating different product categories while preserving the information required for each instrument.

The coordination of different trading instruments is another important consideration in BIHE’s multi-asset service development. BIHE’s integrated product framework focuses on how these trading functions can be organized within a coordinated platform environment while preserving the operating characteristics of each instrument. The company is examining the relationship between market information displays, product selection, order placement, and position management across different asset categories. This approach forms part of BIHE’s broader “One Account, Multiple Assets” development concept, which aims to connect diversified trading tools through a more integrated service structure without treating different financial instruments as interchangeable.

As digital asset markets continue to develop, BIHE plans to improve its trading functionality, product organization, and account service framework while maintaining clear distinctions between different instruments. The availability of individual products and services remains subject to applicable regulations, regional eligibility requirements, and official platform conditions.

About BIHE

BIHE is a digital asset trading platform focused on trading products and related account services. According to company information, its product development areas include spot transactions, perpetual contracts, standardized options and selected exploratory services. The company also focuses on account information, transaction records and operating procedures. Product availability and participation requirements remain subject to applicable regulations, regional restrictions and official platform rules.

Media Contact

Organization: BIHE

Contact Person: Bihe Official

Website: https://www.bihevip.com

Email: Send Email

Country: United States

Release id: 50939

View source version on King Newswire:
BIHE Advances Multi-Asset Trading Services Through Integrated Product Development

file

The platform outlines how daily strategy results, conditional profit allocations and maturity settlements are reflected in USDC product and account records.

United States, 20th Nov 2026 – Quanticagpt, a financial technology platform focused on AI-assisted quantitative trading, has outlined its approach to recording daily strategy calculations, account credits and settlement at maturity for USDC-denominated quantitative products. Its settlement framework connects product-order information with calculation results and subsequent account balance changes, allowing different stages of a product’s settlement process to be reviewed separately.

The platform uses USDC as the participation and settlement currency for its multi-term products. Its recordkeeping process distinguishes funds committed to a product order, amounts calculated during the product term and subsequent credits made to the available USDC balance.

Recording Funds and Product Orders

Before a product order is confirmed, Quanticagpt’s interface presents information including the participation amount, funding breakdown and applicable product term. Once an order takes effect, the corresponding funds are recorded as a product position. The order details show its effective time, expected maturity date and settlement status.

These records help distinguish the original funding amount from subsequent calculations and balance changes. A product’s recorded position represents funds allocated under its terms, while the available account balance reflects amounts recorded as available for other account activity.

Daily Calculations and Conditional Profit Allocation

Quanticagpt’s described framework calculates strategy results in USDC on a daily basis. The calculations take into account actual strategy gains and losses, costs specified in the product terms and any applicable losses carried forward from previous periods. The company distinguishes between a daily calculation and an amount eligible for allocation. A positive result during one period does not necessarily establish a distributable profit or determine the outcome of the full product term.

When distributable net profit is generated, 65% is allocated to users and 35% to the platform. These percentages describe the division of distributable net profit rather than a fixed return on committed capital. Settlement records identify the amounts subsequently credited to available USDC balances and their posting times. This distinction is relevant because a calculated result and a completed account credit represent different stages of the accounting process.

Visa’s USDC Settlement Development as an Industry Example

The use of digital dollar assets in settlement processes is also receiving attention across established payment systems.

On December 16, 2025, Visa announced the expansion of its USDC settlement program to participating U.S. card issuers and acquirers. Initial banking participants included Cross River Bank and Lead Bank, which began settling obligations with Visa using USDC over the Solana blockchain. The initiative introduced settlement capabilities across weekends and holidays while maintaining existing consumer card payment processes. It illustrates how blockchain-based transfers can be incorporated into established financial operations, where transaction timing, settlement confirmation and account reconciliation remain important.

For Quanticagpt, Visa’s USDC settlement development provides an industry example when examining how settlement-related calculations can be connected with subsequent account entries. Although payment settlement and quantitative trading involve different operating processes, both require clear records of amounts due, completed transactions and the timing of account balance changes.

Connecting Calculations with Account Credits

Within Quanticagpt’s product framework, daily calculation records and account credits serve different purposes. A calculation reflects the result determined under the applicable strategy and product rules. An account credit records an amount subsequently posted to the user’s available USDC balance.

By maintaining these records separately, the platform provides information for reviewing how calculated amounts relate to completed settlements. Recording the credited amount and posting time also helps distinguish an allocation from the resulting movement of funds. The company’s framework therefore places attention on the relationship between product calculations, settlement records and actual account activity.

Settlement at Maturity

At maturity, Quanticagpt calculates the amount due under the terms confirmed when the product order was placed.

The order record shows the settlement result, while the account record reflects the corresponding credit and posting time. These entries allow the original funding amount, any recorded allocations and the final maturity settlement to be reviewed in relation to the same product order. The amount due depends on the applicable product terms and actual strategy results. Reaching a stated maturity date does not independently establish a positive return or guarantee repayment of the full committed amount.

Quanticagpt’s USDC settlement framework focuses on distinguishing daily calculations, conditional allocations and completed account credits. By connecting product-order details with settlement information, the company is organizing records that reflect how amounts are calculated and subsequently recorded throughout a product term.

These records form part of Quanticagpt’s broader approach to account management and transaction reporting within its quantitative trading services.

About Quanticagpt

Quanticagpt is a financial technology platform focused on AI-assisted quantitative trading and related account services. Operated by Quanticagpt Ltd., the platform’s stated activities include multi-term USDC products, grid-based strategy tools, product-order information and settlement-related records. Its account management framework covers product positions, available balances and transaction histories.

Media Contact

Organization: Quanticagpt

Contact Person: Quanticagpt Official

Website: https://www.quanticagpt.com/

Email: Send Email

Country: United States

Release id: 50942

View source version on King Newswire:
Quanticagpt Outlines Daily USDC Calculations and Maturity Settlement Records

file

Toronto, Canada, November 20th, 2026, FinanceWire

  • Alphabet, Amazon, Microsoft and Meta plan more than $700 billion of 2026 capital spending, Sherwood News reported; SIPRI put 2025 world military spending at a record $2.887 trillion.
  • Niobium goes into jet engines and rockets, the Royal Society of Chemistry says. The US has not mined it since 1959, according to the USGS.
  • NiobiumX Mining Inc. (OTC: NIOXF), an early-stage explorer with no resource estimate, holds claims in Quebec beside Niobec, North America’s only producing niobium mine.

Alphabet, Amazon, Microsoft and Meta plan to spend more than $700 billion on capital expenditures in 2026, Sherwood News reported. Amazon alone expects about $220 billion, CEO Andy Jassy said in July.

Military budgets set their own record. World military spending reached $2.887 trillion in 2025, the 11th consecutive annual rise, according to SIPRI.

Those are the budgets behind two familiar groups of shares, defense stocks and AI infrastructure stocks. One metal appears on both sides of the ledger.

NiobiumX (OTC: NIOXF) holds ground beside the only producing niobium mine in North America. Proximity to that mine is not necessarily indicative of mineralization on NiobiumX’s property. See the “Adjacent Properties” disclaimer on the Campaign Disclosure page linked below. The company is an early-stage explorer, and it holds no interest in that mine, Niobec.

Niobium has established defense applications and emerging applications in AI computing. It is one of the critical minerals behind America’s weapons and the next generation of AI computing, used in the jet engines, rocket motors and missiles of the US military and in the superconducting circuits being developed to cut AI’s power and heat. The US produces none of it: according to the US Geological Survey, America has not mined niobium since 1959 and imports all of it.

Defense stocks and the niobium alloy inside jet and rocket engines 

On the defense side, niobium goes into heat-resistant alloys. Inconel 718, a superalloy used in aircraft and land-based gas turbine engines and liquid-fuelled rockets, contains 4.75% to 5.50% niobium plus tantalum, according to maker Special Metals. CSIS calls niobium “indispensable for critical components in hypersonic vehicles.”

Separately, the Congressional Budget Office estimated in September that the US had used between one-half and two-thirds of its stock of certain interceptors, among them Patriot, THAAD, SM-3 and SM-6. Rebuilding could take at least five years, Defense News reported on the CBO estimate. These figures do not indicate the niobium content of these interceptors.

In the US, steels take about 77% of niobium use and superalloys about 23%, the USGS says.

AI stocks and the niobium compound in next-generation chips 

Electricity demand from data centers rose 17% in 2025, against 3% growth in global demand, the International Energy Agency says. The agency projects data-center electricity use will roughly double, from 485 terawatt-hours in 2025 to 950 in 2030.

On September 7, 2026, the research institute imec reported circuits built on niobium titanium nitride using standard 300 mm wafers. imec says superconducting technology has the potential to outperform state-of-the-art CMOS by 100 times in energy efficiency. That figure is imec’s estimate, and superconducting computing remains at the research and early development stage. Its program targets “foundries, hyperscalers and system companies.”

Which country is the largest producer of niobium?

Brazil. It accounts for about 93% of global production and Canada about 5%, according to the US Geological Survey’s 2026 niobium data. US imports are worth about $525 million a year.

Ownership matters for anyone researching niobium stocks. CBMM, which CSIS says controls three-quarters of Brazil’s output, is privately held. Niobec in Quebec, the only primary niobium producer outside Brazil according to its owner, has been private since 2015. A Nebraska project is developing what would be the only US niobium mine, but it is not producing, the USGS says.

NIOXF: the Quebec claims beside North America’s only niobium mine 

NiobiumX’s Shipshaw Property comprises 48 mineral claims totalling about 2,686 hectares in the Saguenay region of Quebec, the company says. It also says its nearest claim boundary lies less than 2 km from Niobec’s mining-lease boundary. Proximity to Niobec is not necessarily indicative of mineralization on the Shipshaw Property. See the “Adjacent Properties” disclaimer on the Campaign Disclosure page linked below. The Shipshaw carbonatite is one of five carbonatite intrusions in the Waswanipi-Saguenay zone that Géologie Québec selected for characterization in a 2024 metallogenic bulletin, according to the company. Selection for characterization does not establish the presence of niobium mineralization.

Shipshaw has no resource estimate, and proximity to a producing mine does not mean similar mineralization. Its next steps are set out in the company’s October exploration update, and company information is at niobiumx.com.

About Us

NiobiumX Mining Inc. is a Canadian mineral exploration company focused on niobium and rare earth elements. The Company’s principal asset is the Shipshaw Property, a package of 48 mineral claims totalling approximately 2,686 hectares in the Saguenay region of Québec, situated within the Saguenay Graben of the Grenville Geological Province. The Shipshaw carbonatite is one of five carbonatite intrusions in the Waswanipi-Saguenay zone selected for characterization by Géologie Québec in metallogenic bulletin BM 2024-02. The Company has no current mineral resource or reserve estimate on the property. Niobium is designated a critical mineral by Canada, the United States, the European Union and Australia.

Key facts

  • Alphabet, Amazon, Microsoft and Meta 2026 capital spending plans: more than $700 billion (Sherwood News)
  • Amazon’s expected 2026 capital spending: about $220 billion (CEO Andy Jassy)
  • World military spending, 2025: a record $2.887 trillion (SIPRI)
  • US niobium imports: about $525 million a year (USGS)
  • US niobium end use: steels about 77%, superalloys about 23% (USGS)
  • Shipshaw Property: 48 claims, about 2,686 hectares (NiobiumX)

Campaign Disclosure

Click here to read the full NiobiumX Mining Inc. campaign disclosure, including details regarding the publisher’s compensation, conflicts of interest, and other important disclaimers relating to these materials.

Contact

President
Kirby Renton
NiobiumX Mining Inc.
contact@niobiumx.com

Toronto, Canada, November 20th, 2026, FinanceWire

  • Alphabet, Amazon, Microsoft and Meta plan more than $700 billion of 2026 capital spending, Sherwood News reported; SIPRI put 2025 world military spending at a record $2.887 trillion.
  • Niobium goes into jet engines and rockets, the Royal Society of Chemistry says. The US has not mined it since 1959, according to the USGS.
  • NiobiumX Mining Inc. (OTC: NIOXF), an early-stage explorer with no resource estimate, holds claims in Quebec beside Niobec, North America’s only producing niobium mine.

Alphabet, Amazon, Microsoft and Meta plan to spend more than $700 billion on capital expenditures in 2026, Sherwood News reported. Amazon alone expects about $220 billion, CEO Andy Jassy said in July.

Military budgets set their own record. World military spending reached $2.887 trillion in 2025, the 11th consecutive annual rise, according to SIPRI.

Those are the budgets behind two familiar groups of shares, defense stocks and AI infrastructure stocks. One metal appears on both sides of the ledger.

NiobiumX (OTC: NIOXF) holds ground beside the only producing niobium mine in North America. Proximity to that mine is not necessarily indicative of mineralization on NiobiumX’s property. See the “Adjacent Properties” disclaimer on the Campaign Disclosure page linked below. The company is an early-stage explorer, and it holds no interest in that mine, Niobec.

Niobium has established defense applications and emerging applications in AI computing. It is one of the critical minerals behind America’s weapons and the next generation of AI computing, used in the jet engines, rocket motors and missiles of the US military and in the superconducting circuits being developed to cut AI’s power and heat. The US produces none of it: according to the US Geological Survey, America has not mined niobium since 1959 and imports all of it.

Defense stocks and the niobium alloy inside jet and rocket engines 

On the defense side, niobium goes into heat-resistant alloys. Inconel 718, a superalloy used in aircraft and land-based gas turbine engines and liquid-fuelled rockets, contains 4.75% to 5.50% niobium plus tantalum, according to maker Special Metals. CSIS calls niobium “indispensable for critical components in hypersonic vehicles.”

Separately, the Congressional Budget Office estimated in September that the US had used between one-half and two-thirds of its stock of certain interceptors, among them Patriot, THAAD, SM-3 and SM-6. Rebuilding could take at least five years, Defense News reported on the CBO estimate. These figures do not indicate the niobium content of these interceptors.

In the US, steels take about 77% of niobium use and superalloys about 23%, the USGS says.

AI stocks and the niobium compound in next-generation chips 

Electricity demand from data centers rose 17% in 2025, against 3% growth in global demand, the International Energy Agency says. The agency projects data-center electricity use will roughly double, from 485 terawatt-hours in 2025 to 950 in 2030.

On September 7, 2026, the research institute imec reported circuits built on niobium titanium nitride using standard 300 mm wafers. imec says superconducting technology has the potential to outperform state-of-the-art CMOS by 100 times in energy efficiency. That figure is imec’s estimate, and superconducting computing remains at the research and early development stage. Its program targets “foundries, hyperscalers and system companies.”

Which country is the largest producer of niobium?

Brazil. It accounts for about 93% of global production and Canada about 5%, according to the US Geological Survey’s 2026 niobium data. US imports are worth about $525 million a year.

Ownership matters for anyone researching niobium stocks. CBMM, which CSIS says controls three-quarters of Brazil’s output, is privately held. Niobec in Quebec, the only primary niobium producer outside Brazil according to its owner, has been private since 2015. A Nebraska project is developing what would be the only US niobium mine, but it is not producing, the USGS says.

NIOXF: the Quebec claims beside North America’s only niobium mine 

NiobiumX’s Shipshaw Property comprises 48 mineral claims totalling about 2,686 hectares in the Saguenay region of Quebec, the company says. It also says its nearest claim boundary lies less than 2 km from Niobec’s mining-lease boundary. Proximity to Niobec is not necessarily indicative of mineralization on the Shipshaw Property. See the “Adjacent Properties” disclaimer on the Campaign Disclosure page linked below. The Shipshaw carbonatite is one of five carbonatite intrusions in the Waswanipi-Saguenay zone that Géologie Québec selected for characterization in a 2024 metallogenic bulletin, according to the company. Selection for characterization does not establish the presence of niobium mineralization.

Shipshaw has no resource estimate, and proximity to a producing mine does not mean similar mineralization. Its next steps are set out in the company’s October exploration update, and company information is at niobiumx.com.

About Us

NiobiumX Mining Inc. is a Canadian mineral exploration company focused on niobium and rare earth elements. The Company’s principal asset is the Shipshaw Property, a package of 48 mineral claims totalling approximately 2,686 hectares in the Saguenay region of Québec, situated within the Saguenay Graben of the Grenville Geological Province. The Shipshaw carbonatite is one of five carbonatite intrusions in the Waswanipi-Saguenay zone selected for characterization by Géologie Québec in metallogenic bulletin BM 2024-02. The Company has no current mineral resource or reserve estimate on the property. Niobium is designated a critical mineral by Canada, the United States, the European Union and Australia.

Key facts

  • Alphabet, Amazon, Microsoft and Meta 2026 capital spending plans: more than $700 billion (Sherwood News)
  • Amazon’s expected 2026 capital spending: about $220 billion (CEO Andy Jassy)
  • World military spending, 2025: a record $2.887 trillion (SIPRI)
  • US niobium imports: about $525 million a year (USGS)
  • US niobium end use: steels about 77%, superalloys about 23% (USGS)
  • Shipshaw Property: 48 claims, about 2,686 hectares (NiobiumX)

Campaign Disclosure

Click here to read the full NiobiumX Mining Inc. campaign disclosure, including details regarding the publisher’s compensation, conflicts of interest, and other important disclaimers relating to these materials.

Contact

President
Kirby Renton
NiobiumX Mining Inc.
contact@niobiumx.com

Amsterdam, Netherlands, 20th Nov 2026 – The global life sciences landscape is undergoing a structured realignment as precision medicine establishes itself as a foundational pillar of biopharmaceutical research and therapeutic development. Historically, pharmaceutical methodologies relied predominantly on broad-population models, applying standardized therapeutic interventions across heterogeneous patient cohorts. However, advances in high-throughput genomic sequencing, molecular profiling, and computational biology have fundamentally transformed this paradigm. Modern drug development strategies increasingly prioritize targeted mechanisms of action informed by distinct biological markers and individual genetic variations. As research institutions and commercial developers direct resources toward stratified medicine, the sector is witnessing a systemic shift toward therapeutic frameworks designed around biological specificity and diagnostic validation. This strategic transition reflects a broader recognition that clinical variance can be addressed through disciplined molecular characterization rather than generalized intervention models.

Precision Medicine Emerges as a Major Focus for Healthcare Innovation in 2027

Within this evolving environment, revueltobio focuses its analytical and scientific efforts on the strategic intersection of molecular biology, pharmaceutical research, and computational methodologies. The identification of novel therapeutic targets now depends heavily on the capacity to process intricate biological datasets, decipher complex cellular signaling networks, and evaluate patient stratification criteria at earlier stages of development. By concentrating on the scientific concepts underpinning personalized therapeutic interventions, revuelto365 engages with the foundational questions that govern how targeted therapies move from initial conceptualization toward practical application in modern healthcare environments. In doing so, the organization prioritizes structural frameworks that align mechanistic research with translational potential across distinct disease profiles.

A critical dimension of this scientific transition is the growing reliance on advanced computational tools to enhance traditional laboratory workflows. The integration of artificial intelligence and machine learning within preclinical exploration has enabled research teams to analyze macromolecular structures, predict pharmacokinetic behaviors, and screen chemical libraries with higher analytical fidelity. In tracking these methodologies, revueltobio examines how computational biology can be systematically harmonized with empirical biological research to reduce timelines and resource expenditure in discovery programs. Through initiatives such as revuelto365, the organization assesses ongoing developments across analytical chemistry, biocomputing, and molecular modeling, tracking how these technologies contribute to more targeted, reliable scientific outcomes. The objective remains focused on evaluating computational models that can reliably reflect biological complexity without losing fidelity during empirical testing.

The implementation of precision healthcare frameworks also requires rigorous attention to diagnostic infrastructure and biomarker discovery. Therapeutic efficacy in stratified patient populations is intrinsically linked to the availability of robust diagnostic tools capable of identifying cellular anomalies, genetic predispositions, and disease-specific protein signatures. As biopharmaceutical organizations explore novel intervention pathways, understanding the interplay between genetic profiling and molecular mechanisms becomes paramount. revueltobio directs significant attention to these interdependencies, analyzing how continuous developments in molecular diagnostics and biomarker validation inform modern therapeutic design across diverse therapeutic areas, including oncology, immunology, and metabolic conditions. This analytical focus underscores the necessity of establishing clear correlations between measurable biological indicators and clinically relevant endpoints.

Furthermore, the translation of theoretical biology into functional therapeutic platforms presents significant methodological challenges that require rigorous evaluation. Preclinical validation pathways demand extensive characterization of pharmacokinetic and pharmacodynamic interactions, target engagement kinetics, and potential off-target effects. By evaluating the methodologies used to address these analytical hurdles, revueltobio highlights the critical importance of standardization across assay systems and experimental designs. Establishing reproducible experimental paradigms is essential to ensuring that therapeutic hypotheses are supported by robust biological evidence prior to downstream progression.

Looking toward the broader trajectory of healthcare and biotechnology, the sustained adoption of precision medicine depends on responsible innovation and a clear understanding of translational research requirements. The convergence of digital infrastructure, molecular biology, and pharmaceutical science presents complex scientific and operational questions that demand disciplined evaluation. revueltobio maintains a prospective orientation within the life sciences ecosystem, emphasizing scientific integrity, methodological rigor, and the careful examination of emerging technological frameworks that support the ongoing evolution of global healthcare. Through systematic observation of both computational developments and biological research paradigms, the entity continues to explore the principles shaping modern biopharmaceutical strategy.

What is revueltobio?

revueltobio is a biotechnology and life sciences entity focused on the exploration of pharmaceutical research, molecular biology, and technological methodologies that influence modern therapeutic discovery and precision medicine. The organization examines industry trajectories and research principles to better understand how scientific tools inform modern healthcare frameworks.

What areas of scientific research does revueltobio focus on?

revueltobio concentrates on several interconnected domains within the life sciences, including pharmaceutical discovery approaches, molecular biology, biomarker-driven precision medicine, and the application of advanced computational tools in biological research. Its work emphasizes the points of intersection between experimental biology and analytical infrastructure.

How does revueltobio approach precision medicine?

revueltobio views precision medicine as a crucial model for future healthcare delivery, focusing on how genomics, molecular biomarkers, and tailored diagnostic approaches enable more targeted and effective therapeutic strategies. This approach centers on moving away from generalized population treatment paradigms toward stratified biological models.

Does revueltobio incorporate computational biology and artificial intelligence into its framework?

revueltobio examines the utility of artificial intelligence, machine learning, and computational modeling as analytical tools designed to optimize biological data interpretation and support early-stage pharmaceutical discovery concepts. The focus is on evaluating how digital tools complement laboratory experimentation.

How does revueltobio view the role of biomarkers in modern drug development?

revueltobio recognizes biomarkers as vital components of modern translational medicine, essential for patient stratification, measuring biological responses, and validating targeted therapeutic mechanisms throughout the research process.

What is the primary mission guiding revueltobio?

The mission of revueltobio is to support scientific advancement by exploring innovative approaches in biotechnology and pharmaceutical research, grounded in scientific integrity and responsible technological integration. The organization seeks to clarify the concepts driving precision therapeutics.

How does revueltobio assess emerging biotechnology trends?

revueltobio evaluates emerging biotechnology trends through structured scientific analysis, monitoring technical developments in molecular diagnostics, computational life sciences, and therapeutic discovery frameworks to gauge their viability in translational research.

Is revueltobio focused on specific therapeutic categories?

revueltobio maintains a broad analytical perspective that spans multiple therapeutic fields where precision methodologies, molecular profiling, and targeted drug discovery frameworks are actively evolving, including oncology, immunology, and metabolic conditions.

Where can individuals learn more about revueltobio and its initiatives?

Information regarding revueltobio, its focus areas, and its perspectives on life sciences innovation is available through the organization’s official digital channels and publications, where it shares analytical insights into biotechnology developments.

About revueltobio

RevueltoBio – Advancing Biotechnology and Pharmaceutical Innovation

revuelto365 is a biotechnology and life sciences company focused on exploring the future of pharmaceutical research, drug discovery, and healthcare innovation. Through a science-driven approach, we aim to contribute to the advancement of modern medicine by bringing together emerging technologies, scientific knowledge, and innovative research concepts.

Our areas of interest span pharmaceutical development, molecular biology, biotechnology, precision medicine, and next-generation therapeutic technologies. We recognize the growing importance of artificial intelligence, computational biology, and advanced analytical methods in shaping the future of drug discovery and pharmaceutical research.

Our Mission

Our mission is to support scientific progress by exploring innovative approaches to pharmaceutical research and biotechnology. We believe that responsible innovation, scientific integrity, and technological advancement are essential to addressing the evolving challenges of global healthcare.

Our Vision

Our vision is a future in which biotechnology and pharmaceutical innovation contribute to more precise, efficient, and accessible healthcare solutions worldwide.

Our Areas of Focus

– Pharmaceutical Research: Exploring scientific approaches and emerging technologies relevant to modern drug discovery and development. – Biotechnology Innovation: Examining advances in molecular biology, biological sciences, and next-generation therapeutic technologies. – Precision Medicine: Supporting awareness of personalized healthcare approaches informed by genetics, biomarkers, and advanced diagnostics. – Artificial Intelligence in Healthcare: Exploring the potential of AI, machine learning, and computational technologies in pharmaceutical research. – Life Sciences: Following scientific developments that may shape the future of medicine, biotechnology, and global healthcare.

Looking Toward the Future

As biotechnology continues to evolve, RevueltoBio is committed to a forward-looking perspective that emphasizes scientific knowledge, responsible innovation, and the potential of emerging technologies.

We believe the future of healthcare will be shaped by the convergence of biological sciences, advanced computing, and pharmaceutical innovation.

RevueltoBio — Exploring Science. Advancing Possibilities.

Media Contact

Organization: revueltobio

Contact Person: Daniel Vermeer

Website: https://revueltobio.com

Email: Send Email

Address: 123 Science Park

City: Amsterdam

Country: Netherlands

Release id: 50976

View source version on King Newswire:
Precision Medicine Emerges as a Major Focus for Healthcare Innovation in 2027

file

Australia, 20th Nov 2026 – Neuralia TMS, a specialist provider of transcranial magnetic stimulation (TMS) in Perth, Western Australia, has announced a plain breakdown of how funding works for patients considering TMS therapy, covering Medicare, referrals and private health insurance. According to the company, the explanation sets out which parts of a course are funded, which are not, and where patients are asked to confirm their circumstances before booking.

Neuralia TMS provides a non-invasive form of brain stimulation (link pending) in a specialised TMS suite, the company said. TMS uses an electromagnetic coil placed against the scalp to deliver magnetic pulses, and treatment is arranged as a course of sessions rather than a single visit. The company also offers transcranial direct current stimulation, known as tDCS, and pharmacogenetic testing, with clinics in Como, Kardinya and Armadale.

What the Announcement Means for Medicare Patients

Medicare is Australia’s public health insurance scheme, and some services attract a Medicare rebate when set criteria are met. According to Neuralia TMS, most patients on an initial Medicare-funded course pay $0 out of pocket for TMS at the clinic. The company states that Medicare covers up to 35 sessions in an initial course, and that a course is typically delivered five times a week over four to six weeks.

“Patients should be able to see what Medicare funds and what it does not before they book,” said Dr Shanek Wick, Medical Director of Neuralia TMS. “Eligibility depends on each person’s history, which is why the clinic asks patients to check their circumstances with the team.”

The company also states that a rebate applies only when every eligibility requirement is met. Previous TMS in any setting rules out the initial-course Medicare item, Neuralia TMS said, and an earlier course of treatment on its own does not show that a patient qualifies for a rebate. Patients are asked to contact the clinic about their circumstances, and the company refers them to a separate article on Medicare coverage for the full criteria.

How Referrals, Retreatment and Maintenance Work in Practice

A referral from a general practitioner or psychiatrist starts the Medicare eligibility process, although a referral does not establish eligibility by itself. Neuralia TMS says general practitioners can refer patients by Healthlink, fax or email using a standard referral letter, or through a secure online form. A team member then contacts the patient to book the first appointment. The team reviews the patient’s medical history and consults the referring practitioner before a treatment plan is prepared.

Separate arrangements apply to further treatment. Up to 15 retreatment sessions may be covered if needed, starting four months after the initial course, the company said, provided the criteria are met. Stand-alone maintenance TMS outside the initial and retreatment courses is not funded under the Medicare items, according to Neuralia TMS.

Patients who are not eligible for Medicare are directed to ask the clinic about their circumstances before booking. Enquiries from the Department of Veterans’ Affairs community are directed to a dedicated DVA cost resource or to the clinic team.

What Private Health Insurance May and May Not Cover

On private cover, the company says that private health insurance rarely covers the psychiatrist’s professional fees for TMS sessions delivered in a community setting. It advises patients to check with their insurer about those fees before starting treatment. Insurers set their own policy terms, and cover differs between funds and between levels of cover, so the company’s guidance is to confirm the details directly with the insurer rather than assume that a policy applies.

The statements in this release describe the arrangements as Neuralia TMS sets them out, and they do not amount to a promise of coverage for any individual patient. The company said that questions about funding can be put to the clinic by email before an appointment is made.

Looking Ahead

Neuralia TMS said the funding information is intended as a starting point, and that each patient’s position is confirmed individually once a referral has been received and the clinic has reviewed it.

“Clear funding information matters because the rules apply differently to each person, and the aim is for every patient to understand their position before treatment begins,” said Dr Wick. “Patients with questions are welcome to contact the clinic, and the team will go through their circumstances.”

About Neuralia TMS

Neuralia TMS is a Perth based provider of transcranial magnetic stimulation. The company also offers tDCS and pharmacogenetic testing, and its medical director is Dr Shanek Wick, a specialist psychiatrist.

For additional information about TMS therapy cost and related mental health service developments, contact Neuralia TMS by email at info@neuralia.com.au or call 1 6230 3996. The clinic is located at Unit 2A/125 Melville Parade, Marview House, Como, WA 6152.

Media Contact

Organization: Neuralia TMS (Como)

Contact Person: Dr Shanek Wick

Website: https://www.neuraliatms.com.au/

Email: Send Email

Contact Number: +6162303996

Address: Unit 2A/125 Melville Parade

Address 2: Marview House, Como WA 6152

Country: Australia

Release id: 50971

View source version on King Newswire:
Neuralia TMS Breaks Down TMS Therapy Cost and Insurance Options

file

Port Louis, Mauritius, November 20th, 2026, FinanceWire

ANT follows regular US market hours, while ANT.24H trades 24 hours on weekdays. Both are now live on MT5, web and app.

STARTRADER has launched two CFDs referencing Anthropic, which began trading on the Nasdaq Global Select Market under ticker ANT on November 19.

Anthropic, developer of the Claude AI models, priced its IPO at $83 per share on November 18, above its marketed range of $70 to $78, and its shares opened at $111.50 on their first day of trading. Its IPO filing reported first-half 2026 revenue of $16.3 billion, up from $1.16 billion a year earlier.

The launch follows ANTHUSD, STARTRADER’s pre-IPO CFD introduced in June. When SpaceX listed in June, STARTRADER launched its SPCX CFD three days later.

“Clients have had exposure to Anthropic through ANTHUSD since June. Now that its shares are trading, the listed price is what counts. ANT and ANT.24H give clients exposure to it, including outside regular US market hours.” – Peter Karsten, CEO, STARTRADER

Both symbols offer leverage of up to 1:10, subject to applicable entity conditions, with a minimum lot of 0.1 and maximum of 1,000. ANT trades Monday to Friday, 16:30–23:00, while ANT.24H trades Monday 03:00 to Friday 23:55, with a daily break (server time, GMT+2). Spreads and execution conditions may vary with market conditions. Both CFDs provide price exposure only, without share ownership or shareholder rights. Both are available on MT5, web and the STARTRADER APP.

Risk Warning: CFDs are complex financial instruments carrying a high risk of rapid losses due to leverage. Leverage can magnify both profits and losses. Newly listed stocks can be highly volatile. Trading outside regular US market hours may involve wider spreads and lower liquidity. Stop-loss orders may not execute at the requested price. This content is for information only and does not constitute investment advice.

About STARTRADER

STARTRADER is a global multi-asset broker empowering retail and institutional partners to access global markets through a range of platforms, including MetaTrader, STARTRADER APP, and STAR Copy. STARTRADER operates through entities licensed and regulated by authorities including CMA, ASIC, FSCA, FSA and FSC, combining strong governance with a client-first approach, serving both retail clients and partners with a commitment to transparency, reliability, and long-term growth.

Contact

Janna.magabilen
Janna.magabilen@startrader.com

Having opened the Middle East’s first Korean specialty coffee store in Kuwait, ACR is now preparing to represent Korea at World of Coffee Tokyo 2027.

Korea South, 20th Nov 2026 – A Seoul-based specialty coffee brand that started in a small roasting workshop is emerging as one of the more closely watched examples of Korea’s growing coffee export ambitions. ACR (Alegria Coffee Roasters), founded in 2011, has spent the past year and a half building an international footprint that now stretches from the Middle East to a planned appearance at one of the coffee industry’s largest global trade events.

A selection of ACR’s hot and iced coffee.

According to local media reports, ACR opened its first store outside Korea in Kuwait in March 2025, under a master franchise agreement with a Middle Eastern holding company whose other businesses include the burger brand Thinnies as well as construction, interior and marketing operations. ACR has said it is the first Korean specialty coffee brand to enter the Middle East, and that it aims to expand to more than 20 locations across the Middle East and North Africa within five years.

Staff at ACR’s roasting facility.

ACR said interest in bringing the brand abroad has continued to grow since the Kuwait opening, with the company fielding inquiries from potential partners in additional overseas markets. The company has also been selected to join the Roaster Village program at World of Coffee Tokyo, to be held April 28-May 1, 2027 at Tokyo Big Sight, where it will present its coffee as one of a small number of roasteries representing Korea at the event.

ACR’s store interior in Seoul.

The international attention builds on a sourcing and quality system ACR has run since 2011. The company says its beans rank in the top 10 percent of available quality, selected through annual visits to origin countries, and its staff include Q-grader-certified cuppers who have judged international auctions such as the Ecuador Farmers Collection and Best of Yemen. ACR’s roasting operation is HACCP certified, and its five directly operated stores in Seoul’s Gwanghwamun and Pangyo Techno Valley areas are staffed entirely by full-time, professional baristas, serving roughly 300,000 cups of coffee in the first half of 2026 alone.

A barista preparing coffee at ACR.

“When we started, we were a small roastery with almost no sales,” said Giyong Yoo, CEO of ACR. “Opening in Kuwait showed us there’s real demand for Korean specialty coffee outside our home market, and preparing for World of Coffee Tokyo is the next step in introducing ACR to an even wider international audience.”

ACR said it plans to use the Kuwait store and its upcoming Tokyo appearance as a foundation for further overseas growth, while continuing to operate its five Seoul stores and direct-to-consumer sales channels.

About ACR

ACR (Alegria Coffee Roasters) is a Seoul, South Korea-based specialty coffee brand founded in 2011. The company operates five directly run stores in Seoul’s Gwanghwamun and Pangyo Techno Valley areas, roasts under HACCP food-safety certification, and sources beans it says rank in the top 10 percent of available quality through annual origin visits. ACR opened its first overseas location in Kuwait in 2025 and has been selected to join the Roaster Village program at World of Coffee Tokyo 2027. More information: www.acrkorea.com / Instagram @acr_korea

Media Contact

Organization: ACR (Alegria Coffee Roasters)

Contact Person: Giyong Yoo, CEO

Website: https://www.acrkorea.com/

Email: Send Email

Country: Korea South

Release id: 50969

View source version on King Newswire:
Specialty Coffee Success Story: Seoul Coffee Roastery ACR Expands From Kuwait to Tokyo’s World of Coffee

file